Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

A New Stromal Signature Applicable to Formalin-Fixed Paraffin-Embedded Tissues Identifies Patients at Risk in Prospective Clinical Trials of the German High-Grade Non-Hodgkin Lymphoma Study Group

Blood (2018) 132 (Supplement 1): 343.

https://doi.org/10.1182/blood-2018-99-112450

Published: 2018

Journal Articles

Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA

Blood (2018) 132 (Supplement 1): 781.

https://doi.org/10.1182/blood-2018-99-112403

Published: 2018

Journal Articles

Integrative Oncogenomic Analysis Combining Whole Genome, Transcriptome and Epigenome Identifies Altered Chromatin Accessibility Landscape in Multiple Myeloma

Raphael Szalat, MD, Mehmet Kemal Samur, PhD, Christopher J. Ott, PhD, Matthew Lawlor, Charles Epstein, Brian J Abraham, PhD, Charles Y Lin, PhD, Linying Zhang, Rao Prabhala, PhD, Nina Farrell, Kenneth Wes, Yu-Tzu Tai, PhD, Mariateresa Fulciniti, PhD, Giovanni Parmigiani, Richard A. Young, PhD, Kenneth C Anderson, MD, Nikhil Munshi, MD

Blood (2017) 130 (Supplement 1): 328.

https://doi.org/10.1182/blood.V130.Suppl_1.328.328

Published: 2017

Journal Articles

Six Cycles of R-CHOP-21 Is Non-Inferior to 8 Cycles for Treatment of Diffuse Large B-Cell Lymphoma - a Nordic Lymphoma Group Population Based Study

Tove Wästerlid, MD PhD, Jorne Lionel Biccler, MSc, Peter de Nully Brown, MD PhD, Jacob Haaber Christensen, MD PhD, Gunilla Enblad, MD PhD, Judit Mészáros Jørgensen, Karin E Smedby, MD PhD, Tarec Christoffer El-Galaly, MD PhD, Mats Jerkeman, MD PhD

Blood (2017) 130 (Supplement 1): 1560.

https://doi.org/10.1182/blood.V130.Suppl_1.1560.1560

Published: 2017

Journal Articles

Mapping of the Multiple Myeloma Transcriptional Core Regulatory Circuitry Reveals TCF3 As a Novel Dependency and an Oncogenic Collaborator of MYC

Charles Y Lin, PhD, Mariateresa Fulciniti, PhD, Michael A Lopez, BS, Mehmet Kemal Samur, PhD, Raphael Szalat, MD, Christopher J. Ott, PhD, Charles Epstein, Richard A. Young, PhD, James Bradner, MD, Kenneth C Anderson, MD, Nikhil Munshi, MD

Blood (2017) 130 (Supplement 1): 64.

https://doi.org/10.1182/blood.V130.Suppl_1.64.64

Published: 2017

Journal Articles

Age and Gemtuzumab Ozogamicin Influence the Prognostic Impact of TET2 Expression and Splicing in Intensively Treated Patients with Acute Myeloid Leukemia

Antony Ceraulo, Aminetou Mint-Mohamed, Delphine Maucort-Boulch, MD PhD, Helene Lapillone, Guy Leverger, MD, Etienne Paubelle, MD PhD, Xavier Thomas, MD PhD, Olivier Nibourel, PharmD, PhD, Claude Preudhomme, MD PhD, Sylvie Castaigne, MD PhD, Hervé Dombret, Lea Herpe, Christine Ragu, PhD, Yves Bertrand, MD PhD, Franck Mortreux, PhD, Eric Wattel, MD PhD

Blood (2016) 128 (22): 3952.

https://doi.org/10.1182/blood.V128.22.3952.3952

Published: 2016

Journal Articles

Network-Based Analysis of Exome Sequencing Mutations Identifies Molecular Subtypes of Myelodysplastic Syndromes

Aziz Nazha, MD, Bartlomiej Przychodzen, MSc, Hideki Makishima, MD PhD, Hetty E. Carraway, MD MBA, Bhumika J. Patel, Cassandra M Hirsch, Michael Clemente, MS, Srinivasa R. Sanikommu, MBBS, Aaron T. Gerds, MD MS, Jennifer S. Carew, PhD, Satoru Miyano, MD PhD, Matt Kalaycio, MD, Seishi Ogawa, MD PhD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS

Blood (2015) 126 (23): 611.

https://doi.org/10.1182/blood.V126.23.611.611

Published: 2015

Journal Articles

No Increased Risk of Secondary Neoplasms in Patients Treated with Rituximab for Non-Hodgkin’s Lymphoma : A Meta-Analysis of 9 Trials

Isabelle Fleury, MD, Sylvie Chevret, MD PhD, Michael Pfreundschuh, Gilles Salles, MDPhD, Bertrand Coiffier, MD PhD, Marinus H.J. van Oers, Christian Gisselbrecht, MDPhD, Emanuele Zucca, MD, Michael Herold, MDPhD, Michele Ghielmini, MD, Catherine Thieblemont, MDPhD

Blood (2014) 124 (21): 1659.

https://doi.org/10.1182/blood.V124.21.1659.1659

Published: 2014

Journal Articles

Primary Mediastinal B Cell Lymphoma Treated with CHOP-Like Chemotherapy with or without Rituximab: 5-Year Results of the Mabthera International Trial Group (MInT) Study

Mathias Witzens-Harig, MD, Anthony D Ho, MD, Evelyn Kuhnt, Marek Trneny, MD, Michael Rieger, MD, Anders Österborg, MD, PhD, Ruth Pettengell, Robert Stevens, MD, Devinder S Gill, MB ChB, MRCP (UK), FRCPath (Lond), Jan Walewski, Markus Loeffler, Michael Pfreundschuh, MD

Blood (2012) 120 (21): 1612.

https://doi.org/10.1182/blood.V120.21.1612.1612

Published: 2012

Journal Articles

The Impact of Rituximab and Radiotherapy On Treatment Outcome of Patients with DLBCL and Skeletal Involvement

Gerhard Held, MD, Samira Zeynalova, PhD, Niels Murawski, MD, Marita Ziepert, PhD, Barbara Kempf, MD, Andreas Viardot, MD, Martin Dreyling, Michael Hallek, MD, Mathias Witzens-Harig, MD, Christian Ruebe, MD, Christian Berdel, MD, Carsten Zwick, MD, Norbert Schmitz, MD, Michael Pfreundschuh, MD

Blood (2012) 120 (21): 690.

https://doi.org/10.1182/blood.V120.21.690.690

Published: 2012

Journal Articles

Parenthood in Long-Term Survivors After CHOEP Treatment for Aggressive Lymphoma Is Not Significantly Impaired in Comparison to the General Population. Results From the Mabthera International Trial (MInT) and the DSHNHL NHLB1 Study

Julia Meissner, MD, Sascha Dietrich, MD, Marita Ziepert, PhD, Evelyn Kuhnt, Tanja Rixecker, Mathias Witzens-Harig, MD, Michael Pfreundschuh, MD, Anthony D Ho, MD

Blood (2012) 120 (21): 3649.

https://doi.org/10.1182/blood.V120.21.3649.3649

Published: 2012

Journal Articles

High Rate of Initial Treatment Failure in Patients with Primary Mediastinal B-Cell Lymphoma Treated with R-CHOP

Jeremy S. Abramson, MD, Matthew D Hellmann, MD, Yang Feng, PhD, Jeffrey A. Barnes, MD, PhD, Tak Takvorian, MD, Christiana E. Toomey, Michael Sheppard, James S. Michaelson, PhD, Donna Neuberg, ScD, Ephraim P. Hochberg, MD

Blood (2011) 118 (21): 1601.

https://doi.org/10.1182/blood.V118.21.1601.1601

Published: 2011

Journal Articles

CNS Disease In Younger Patients (<=60 years) with Aggressive Lymphoma Treated In Trials of the German High Grade Non Hodgkin Lymphoma Study Group (DSHNHL) and the MabThera International Trial (MInT)

Norbert Schmitz, MD, Samira Zeynalova, Bertram Glass, MD, Ulrich Kaiser, MD, Eva Cavallin-Stahl, MD, Max Wolf, MBBS, FRACP, FRCPA, Mathias Haenel, MD, Markus Loeffler, MD, Lorenz Trümper, MD, M. Pfreundschuh

Blood (2010) 116 (21): 112.

https://doi.org/10.1182/blood.V116.21.112.112

Published: 2010

Journal Articles

Outcome of Patients with Chemotherapy Refractory and Early Progressive Diffuse Large B Cell Lymphoma After R-CHOP Treatment

Felicitas Hitz, Joseph M. Connors, MD, Randy D. Gascoyne, MD, Paul Hoskins, Alden A. Moccia, Kerry Joanne Savage, MD, BSc, MSc, Laurie H. Sehn, MD, MPH, Tamara Shenkier, Richard Klasa, MD, CM, FRCP(C)

Blood (2010) 116 (21): 1751.

https://doi.org/10.1182/blood.V116.21.1751.1751

Published: 2010

Journal Articles

Randomised Intergroup Trial of First line Treatment for young Low-Risk Patients (<61 years) with Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL) with a CHOP-like Regimen with or without the Anti-CD20 Antibody Rituximab – 6-Year Follow-up of the Mint Study of the Mabthera International Trial (MInT) Group

Blood (2010) 116 (21): 111.

https://doi.org/10.1182/blood.V116.21.111.111

Published: 2010

Journal Articles

The Role of the Rituximab Partner Chemotherapy Regimen In Young Patients with Good-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL): Results of the 6-Year Follow-up of the Mint Study of the Mabthera International Trial (MInT) Group.

Niels Murawski, MD, Evelyn Kuhnt, Sandra Grass, MD, Wolfgang Hiddemann, MD, Eva Cavallin-Stahl, MD, Georg Hess, MD, Mathias Witzens-Harig, Ingrid Vasova, MD, Ulrich Jäger, MD, Michal Osowiecki, MD, Scott North, MD, Ruth Pettengell, FRACP, PhD, Viola Pöschel, Markus Löffler, Michael Pfreundschuh, MD

Blood (2010) 116 (21): 2826.

https://doi.org/10.1182/blood.V116.21.2826.2826

Published: 2010

Journal Articles

LRF Critically Regulates Mature B Cell Fate and Germinal Center Response Via Notch-Dependent and -Independent Mechanisms.

Nagisa Sakurai, Manami Maeda, Sung-UK Lee, Toshiki Saito, Shigeru Chiba, Julie Teruya-Feldstein, Takahiro Maeda

Blood (2009) 114 (22): 1961.

https://doi.org/10.1182/blood.V114.22.1961.1961

Published: 2009

Journal Articles

Aggressive Chemotherapy (CHOEP-14) and Rituximab or High-Dose Therapy (MegaCHOEP) and Rituximab for Young, High-Risk Patients with Aggressive B-Cell Lymphoma: Results of the MegaCHOEP Trial of the German High — Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

Norbert Schmitz, Maike Nickelsen, Marita Ziepert, Matthias Haenel, Peter Borchmann, PD, Dr., Andreas Viardot, Christina Nickenig, Martin Bentz, MD, Christian Peschel, MD, Lorenz Trümper, Markus Loeffler, Michael Pfreundschuh, Bertram Glass, MD, PhD

Blood (2009) 114 (22): 404.

https://doi.org/10.1182/blood.V114.22.404.404

Published: 2009

Journal Articles

NK-Like Homeodomain Proteins Regulate NOTCH3-Signaling in T-Cells.

Stefan Nagel, PhD, Letizia Venturini, Grzegorz K. Przybylski, Piotr Grabarczyk, Corinna Meyer, Maren Kaufmann, Karin Battmer, Christian A. Schmidt, Hans G. Drexler, Michaela Scherr, Roderick A.F. MacLeod

Blood (2008) 112 (11): 1194.

https://doi.org/10.1182/blood.V112.11.1194.1194

Published: 2008

NARROW

A New Stromal Signature Applicable to Formalin-Fixed Paraffin-Embedded Tissues Identifies Patients at Risk in Prospective Clinical Trials of the German High-Grade Non-Hodgkin Lymphoma Study Group

Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA

Integrative Oncogenomic Analysis Combining Whole Genome, Transcriptome and Epigenome Identifies Altered Chromatin Accessibility Landscape in Multiple Myeloma

Six Cycles of R-CHOP-21 Is Non-Inferior to 8 Cycles for Treatment of Diffuse Large B-Cell Lymphoma - a Nordic Lymphoma Group Population Based Study

Mapping of the Multiple Myeloma Transcriptional Core Regulatory Circuitry Reveals TCF3 As a Novel Dependency and an Oncogenic Collaborator of MYC

Age and Gemtuzumab Ozogamicin Influence the Prognostic Impact of TET2 Expression and Splicing in Intensively Treated Patients with Acute Myeloid Leukemia

R-CHOP in Primary Mediastinal B-Cell Lymphoma (PMBL): Results from the UK NCRI R-CHOP 14 v 21 Trial

Network-Based Analysis of Exome Sequencing Mutations Identifies Molecular Subtypes of Myelodysplastic Syndromes

No Increased Risk of Secondary Neoplasms in Patients Treated with Rituximab for Non-Hodgkin’s Lymphoma : A Meta-Analysis of 9 Trials

Primary Mediastinal B Cell Lymphoma Treated with CHOP-Like Chemotherapy with or without Rituximab: 5-Year Results of the Mabthera International Trial Group (MInT) Study

The Impact of Rituximab and Radiotherapy On Treatment Outcome of Patients with DLBCL and Skeletal Involvement

Parenthood in Long-Term Survivors After CHOEP Treatment for Aggressive Lymphoma Is Not Significantly Impaired in Comparison to the General Population. Results From the Mabthera International Trial (MInT) and the DSHNHL NHLB1 Study

High Rate of Initial Treatment Failure in Patients with Primary Mediastinal B-Cell Lymphoma Treated with R-CHOP

CNS Disease In Younger Patients (<=60 years) with Aggressive Lymphoma Treated In Trials of the German High Grade Non Hodgkin Lymphoma Study Group (DSHNHL) and the MabThera International Trial (MInT)

Outcome of Patients with Chemotherapy Refractory and Early Progressive Diffuse Large B Cell Lymphoma After R-CHOP Treatment

The Role of the Rituximab Partner Chemotherapy Regimen In Young Patients with Good-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL): Results of the 6-Year Follow-up of the Mint Study of the Mabthera International Trial (MInT) Group.

LRF Critically Regulates Mature B Cell Fate and Germinal Center Response Via Notch-Dependent and -Independent Mechanisms.

Aggressive Chemotherapy (CHOEP-14) and Rituximab or High-Dose Therapy (MegaCHOEP) and Rituximab for Young, High-Risk Patients with Aggressive B-Cell Lymphoma: Results of the MegaCHOEP Trial of the German High — Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

NK-Like Homeodomain Proteins Regulate NOTCH3-Signaling in T-Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only